Literature DB >> 10223547

Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). Study Group for Vertical Transmission.

C Mazza1, A Ravaggi, A Rodella, M Duse, D Padula, M Lomini, F Castelli, S Bresciani, A Albertini, E Cariani.   

Abstract

Forty-four anti-HIV seropositive pregnant women were enrolled in a study of maternal factors related to mother-to-infant human immunodeficiency virus type 1 (HIV-1) transmission. HIV-1 infection was documented in 11 of 45 infants (24.4%). Obstetric factors, maternal CD4 counts, and disease stage were not related to the risk of transmission. HIV-1 RNA levels at delivery were significantly higher in mothers who transmitted the infection (P = .024). A strong relationship between viral load and risk of transmission was observed in women with stage A1 (P= .006), but not in those with stages A2-A3. These results suggest that vertical transmission of HIV-1 is multifactorial and that viral load plays a major role in mothers with early-stage HIV-1 infection.

Entities:  

Mesh:

Year:  1999        PMID: 10223547     DOI: 10.1002/(sici)1096-9071(199905)58:1<59::aid-jmv9>3.0.co;2-5

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

1.  Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection.

Authors:  John S Lambert; Jack Moye; Susan F Plaeger; E Richard Stiehm; James Bethel; Lynne M Mofenson; Bonnie Mathieson; Jonathan Kagan; Howard Rosenblatt; Helene Paxton; Hildie Suter; Alan Landay
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

2.  Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective study.

Authors:  Paul Kamara; Loyda Melendez-Guerrero; Miguel Arroyo; Heidi Weiss; Pauline Jolly
Journal:  Virol J       Date:  2005-02-24       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.